Zymeworks Statistics
Total Valuation
Zymeworks has a market cap or net worth of $593.92 million. The enterprise value is $274.01 million.
| Market Cap | 593.92M |
| Enterprise Value | 274.01M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, after market close.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Zymeworks has 70.70 million shares outstanding. The number of shares has increased by 14.24% in one year.
| Shares Outstanding | 70.70M |
| Shares Change (YoY) | +14.24% |
| Shares Change (QoQ) | +7.68% |
| Owned by Insiders (%) | 4.03% |
| Owned by Institutions (%) | 98.43% |
| Float | 42.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.77 |
| Forward PS | 7.01 |
| PB Ratio | 1.36 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.43 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.92, with a Debt / Equity ratio of 0.06.
| Current Ratio | 6.92 |
| Quick Ratio | 6.61 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -28.40% and return on invested capital (ROIC) is -32.08%.
| Return on Equity (ROE) | -28.40% |
| Return on Assets (ROA) | -22.00% |
| Return on Capital (ROIC) | -32.08% |
| Revenue Per Employee | $183,505 |
| Profits Per Employee | -$458,087 |
| Employee Count | 275 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.88M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.10% in the last 52 weeks. The beta is 1.18, so Zymeworks's price volatility has been higher than the market average.
| Beta (5Y) | 1.18 |
| 52-Week Price Change | -2.10% |
| 50-Day Moving Average | 8.77 |
| 200-Day Moving Average | 9.14 |
| Relative Strength Index (RSI) | 41.94 |
| Average Volume (20 Days) | 544,374 |
Short Selling Information
The latest short interest is 3.04 million, so 4.30% of the outstanding shares have been sold short.
| Short Interest | 3.04M |
| Short Previous Month | 3.74M |
| Short % of Shares Out | 4.30% |
| Short % of Float | 7.09% |
| Short Ratio (days to cover) | 4.71 |
Income Statement
In the last 12 months, Zymeworks had revenue of $50.46 million and -$125.97 million in losses. Loss per share was -$1.78.
| Revenue | 50.46M |
| Gross Profit | 50.46M |
| Operating Income | -148.57M |
| Pretax Income | -127.86M |
| Net Income | -125.97M |
| EBITDA | -111.14M |
| EBIT | -127.86M |
| Loss Per Share | -$1.78 |
Balance Sheet
The company has $345.05 million in cash and $25.13 million in debt, giving a net cash position of $319.92 million or $4.52 per share.
| Cash & Cash Equivalents | 345.05M |
| Total Debt | 25.13M |
| Net Cash | 319.92M |
| Net Cash Per Share | $4.52 |
| Equity (Book Value) | 438.00M |
| Book Value Per Share | 6.19 |
| Working Capital | 336.93M |
Cash Flow
In the last 12 months, operating cash flow was -$72.78 million and capital expenditures -$2.27 million, giving a free cash flow of -$75.05 million.
| Operating Cash Flow | -72.78M |
| Capital Expenditures | -2.27M |
| Free Cash Flow | -75.05M |
| FCF Per Share | -$0.99 |
Margins
Gross margin is 100.00%, with operating and profit margins of -294.42% and -249.63%.
| Gross Margin | 100.00% |
| Operating Margin | -294.42% |
| Pretax Margin | -253.36% |
| Profit Margin | -249.63% |
| EBITDA Margin | -220.24% |
| EBIT Margin | -253.36% |
| FCF Margin | -148.73% |
Dividends & Yields
Zymeworks does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.24% |
| Shareholder Yield | -14.24% |
| Earnings Yield | -21.21% |
| FCF Yield | -12.64% |
Analyst Forecast
The average price target for Zymeworks is $12.67, which is 50.83% higher than the current price. The consensus rating is "Buy".
| Price Target | $12.67 |
| Price Target Difference | 50.83% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 4.68% |
| EPS Growth Forecast (5Y) | -7.30% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zymeworks has an Altman Z-Score of 1.35 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.35 |
| Piotroski F-Score | 3 |